Understanding the 2026 Healthcare Split
A significant healthcare divide is emerging in 2026, creating distinct winners and losers across America’s healthcare landscape. The bifurcation stems from policy decisions made during the last two presidential administrations, resulting in dramatically different outcomes for millions of Americans depending on their insurance coverage.
Some Americans, particularly Medicare beneficiaries, are poised to experience substantial relief from escalating prescription drug costs as the first round of negotiated Medicare drug prices takes effect. Conversely, others face mounting financial pressures as Affordable Care Act (ACA) tax credits expire and Medicaid coverage becomes increasingly precarious amid significant state funding reductions.
This healthcare dichotomy reflects the cumulative impact of legislative actions from both the Biden and Trump administrations. In 2022, President Joe Biden signed the landmark Inflation Reduction Act (IRA), granting Medicare unprecedented authority to negotiate prices on its most expensive prescription medications for the first time in the program’s history. In stark contrast, President Donald Trump’s July signing of the “big, beautiful bill” slashed Medicaid funding while failing to extend critical ACA subsidies.
“If you’re on Medicare, there’s some good news,” explained Larry Levitt, executive vice president for health policy at KFF, a nonpartisan research organization. “If you’re on the ACA or Medicaid, it may be bad news ahead for you.”
Medicare Drug Cost Reductions Take Effect
Historic Price Negotiations Begin January 2026
Starting January 1, 2026, the first wave of negotiated drug prices becomes effective for Medicare enrollees nationwide. These newly negotiated prices apply to the 10 most expensive medications in the Medicare program, representing a transformative shift in pharmaceutical pricing policy. The affected medications include widely prescribed drugs such as the blood thinners Eliquis and Xarelto, along with diabetes medications Jardiance and Januvia. Collectively, these drugs serve nearly 9 million older adults across the United States.
According to a comprehensive report published this month by AARP, out-of-pocket costs for these negotiated drugs are projected to decline by more than 50% on average in 2026. Seven of the 10 medications will cost less than $100 per month, representing unprecedented savings for seniors managing chronic conditions. The Centers for Medicare & Medicaid Services (CMS) estimates enrollees will collectively save $1.5 billion in out-of-pocket expenses during 2026 alone.
Additional Cost Protections for Seniors
The Inflation Reduction Act implemented several additional safeguards protecting Medicare beneficiaries from catastrophic prescription drug expenses. The legislation capped annual out-of-pocket prescription drug spending for Medicare enrollees at $2,000 in 2025, with this limit increasing to $2,100 in 2026. Furthermore, since 2023, out-of-pocket insulin costs have been capped at $35 per month, providing critical relief for diabetic patients.
“The IRA is truly a historic win for millions of seniors,” stated Leigh Purvis, prescription drug policy principal at the AARP Public Policy Institute, during a recent media briefing.
Real-World Impact on Medicare Enrollees
Personal Stories of Healthcare Savings
Tom Howie, an 81-year-old resident of Flint, Michigan, exemplifies how these changes are transforming seniors’ lives. With a extensive history of heart disease, including multiple heart attacks culminating in quadruple bypass surgery in 1997, Howie has long struggled with overwhelming prescription costs.
In previous years, Howie spent as much as $8,000 out of pocket on prescriptions before reaching Medicare’s catastrophic coverage threshold, which he typically hit around mid-summer. Under the new $2,000 cap implemented in 2025, he reached this threshold by May, providing months of additional financial relief.
Currently, Howie pays approximately $121 for a three-month supply of Eliquis, one of his essential cardiac medications. He anticipates this copayment will decrease further in 2026 when the negotiated prices take effect.
“It’s a big difference,” Howie explained. “I just get my Social Security, basically, and then I have some money from my 401(k).” Living on a fixed income, these savings represent substantial financial breathing room for essential expenses.
Unintended Consequences of Drug Price Reform
Rising Launch Prices for New Medications
Despite its considerable benefits, the Inflation Reduction Act has generated some unexpected drawbacks, including higher list prices for newly launched medications, according to Richard Frank, a senior fellow in economic studies and director of the center on health policy at the Brookings Institution.
One IRA provision penalizes pharmaceutical companies for raising prices too sharply year-over-year. As a strategic response, drugmakers are increasingly setting initial prices substantially higher at launch.
A report published in October by the nonprofit Institute for Clinical and Economic Review found that the average net launch price for 154 new drugs increased 51% over three years, from 2022 to 2024, after accounting for inflation and discounts. Notable examples include Leqembi for early Alzheimer’s disease treatment and Casgevy, a groundbreaking gene therapy for sickle cell disease.
“I don’t see any reason to believe that’s not going to at least continue for a bit, until people figure out some sort of policy moves to address that,” Frank cautioned.
ACA and Medicaid Face Uncertain Future
Expiring ACA Subsidies Threaten Coverage
Actions by the Trump administration and Republican lawmakers have introduced substantial uncertainty into healthcare costs for millions of Americans. Enhanced ACA subsidies that helped maintain affordable premiums are expiring after Congressional Republicans declined to extend them. According to KFF analysis, some individuals could pay up to 114% more on average in premiums when combined with insurer rate increases for 2026.
Early enrollment data from state health officials indicates more people are abandoning ACA coverage or switching to cheaper, less comprehensive plans for 2026 compared to the same period last year.
Medicaid Funding Cuts and Coverage Gaps
Changes to Medicaid funding approved under Trump’s “One Big Beautiful Bill,” including eliminating financial incentives for states to expand Medicaid, are scheduled to take effect in January 2026. This means that in the 10 states that haven’t expanded Medicaid, low-income adults will remain in a “coverage gap,” Levitt explained, earning too little to afford ACA coverage but remaining ineligible for Medicaid.
More comprehensive Medicaid changes, including work requirements, are scheduled to commence in 2027.
“That’s going to be one of the biggest changes we’re going to see,” said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. “More and more people won’t have any access to care, and that will theoretically lead to more uncompensated care for hospitals and doctors and more medical debt for people if they actually need to go and get care.”
Trump Administration’s Pharmaceutical Strategy
Most Favored Nation Pricing Model
Despite challenges facing ACA and Medicaid enrollees, individuals outside Medicare might experience drug cost reductions through Trump administration initiatives. President Trump has advocated aligning U.S. prescription drug costs with the lowest prices in other wealthy nations, signing an executive order in May directing federal officials to implement the “most favored nation” pricing model.
The administration has subsequently negotiated deals with 14 pharmaceutical companies, securing combinations of lower prices through direct-to-consumer offers and reduced federal government costs for certain medications in exchange for tariff relief. A new website, TrumpRx.gov, connects consumers to drugmakers’ direct-pay platforms.
Major Deal with GLP-1 Manufacturers
In November, President Trump secured arguably his largest pharmaceutical agreement with Novo Nordisk and Eli Lilly, manufacturers of the weight loss drugs Wegovy and Zepbound. The deal reduced GLP-1 medication costs for out-of-pocket payers not using insurance, while also lowering prices Medicare and Medicaid pay for these drugs, saving taxpayers money.
However, Levitt expressed concerns about this strategy’s sustainability. Unlike the Inflation Reduction Act, which codified pricing provisions into law, Trump’s approach relies on voluntary agreements with drugmakers.
“President Trump has been using the threat of tariffs as leverage with drug companies,” Levitt noted. “If that threat goes away in the future, there won’t be anything holding drug companies back from raising prices again.”
What Lies Ahead for Healthcare Consumers
Affordability Questions Remain
Dusetzina emphasized that TrumpRx’s lower costs may still not make certain drugs affordable for all Americans.
“They’re lower prices for people paying cash, but still not low prices,” Dusetzina explained. “That’s really key. If you can’t afford to keep your health insurance because you’ve lost access to health insurance subsidies, then it seems unlikely that you would have the resources to pay out of pocket for drugs through TrumpRx.”
Potential Congressional Action
Levitt suggested there may still be hope for Americans on ACA plans if Congress reaches an agreement to extend subsidies next year. Republicans held firm against Democratic efforts to extend subsidies by year-end, but a key group of House Republicans broke ranks with Speaker Mike Johnson, R-La., teaming up with Democrats to force a vote sometime in 2026.
The healthcare landscape in 2026 will clearly favor Medicare beneficiaries while creating significant challenges for ACA and Medicaid enrollees, underscoring the complex interplay between legislative decisions and real-world healthcare access and affordability.
Discover the latest GovHealth news updates with a single click. Follow DistilINFO GovHealth and stay ahead with updates. Join our community today!
